Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVOLVE-MI
2021-005272-19Phase 4Active
- Sponsor
- Amgen
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of evolocumab in dyslipidemia and hypercholesterolemia (2 arms), sponsored by Amgen. Started Nov 2022; status: active.
02
Drugs
evolocumab
03
Conditions
dyslipidemiahypercholesterolemia
Beyond the preview
Go deeper on 2021-005272-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005272-19.